Last week, magAssist's second preclinical training on China's first full-maglev extracorporeal VAD with the collaboration of Professor Nianguo Dong's team of the Cardiovascular Surgery Department, Wuhan Union Hospital and Professor Jinsong Huang's team of the Cardiovascular Surgery Department, Guangdong Provincial People's Hospital.
This training was divided into exploration on clinical application timing of extracorporeal artificial heart and surgical methods to be applied. The clinical team completed pipeline connection and machine operation on two sheep which soon came to life and stood up after the surgery.
Professor Jinsong Huang said, "The device features easy use. We can feel that the device designer has made thoughtful consideration of human-factors engineering. We really hope that the clinical trials of extracorporeal VADs can be unfolded in our center and good technologies can be applied to the patients soon."
Professor Ping Li noted, "Extracorporeal VADs are new clinical applications in China and an innovation of treatment concepts. It's hoped that they can fill in the current clinical gap. In terms of support timing and method of blood flow circuit establishment, the overall treatment should be carefully selected on the premise of putting patients first.”
Professor Xufeng Wei pointed out, "Early this year, animal experiments based on GLP standard were completed to verify the safety of the VADs. This clinical training enabled experts from each center to experience the operation of the device and simulate the corresponding surgical methods on animals, which is of great significance to the formal clinical trials."